Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Lupin, Boehringer Ingelheim sign USD 700 million deal for novel oncology drug

      Lupin, Boehringer Ingelheim sign USD 700 million deal for novel oncology drug

      Farhat Nasim4 Sept 2019 5:00 PM IST
      Lupin will receive an upfront payment of $20 million and potential additional payments for successful achievement of defined clinical, regulatory and...
      ICMR orders prosecution against Nestle, top Hospitals including Gangaram, Manipal for clinical trial on premature infants

      ICMR orders prosecution against Nestle, top Hospitals including Gangaram, Manipal for clinical trial on premature infants

      Farhat Nasim3 Sept 2019 3:06 PM IST
      New Delhi: Top-notch hospitals of the country including Manipal Hospital, Ganga Ram Hospital and others have been directed by the Indian Council for...
      DOP junks Cipla plea to refix MRP of Tafmune–EM

      DOP junks Cipla plea to refix MRP of Tafmune–EM

      Farhat Nasim2 Sept 2019 4:34 PM IST
      New Delhi: Through a recent decision, the Department of Pharmaceuticals (DOP) has rejected the review application filed by Cipla Limited against...
      Government Panel refuses to exempt Next Gen DES from price cap

      Government Panel refuses to exempt Next Gen DES from price cap

      Farhat Nasim2 Sept 2019 4:23 PM IST
      New Delhi: Various domestic and multinational stent makers failed to convince the Government to allow the manufacture and sale of drug-eluting stents...
      NovaLead Pharma topical drug Galnobax for Diabetic Foot Ulcer proceeds for phase 3 trial

      NovaLead Pharma topical drug Galnobax for Diabetic Foot Ulcer proceeds for phase 3 trial

      Farhat Nasim2 Sept 2019 9:45 AM IST
      "Development of Galnobax and the clinical trials are also supported by Department of Biotechnology under the BIPP program," said Novalead...
      4WEB Medical gets USFDA clearance for cervical stand-alone interbody fusion device

      4WEB Medical gets USFDA clearance for cervical stand-alone interbody fusion device

      Farhat Nasim2 Sept 2019 9:14 AM IST
      New Delhi: 4WEB Medical, an orthopaedic device company focused on developing implants utilizing its proprietary Truss Implant Technology, announced...
      Delhi HC given Green Signal to Natco Pharma for generic of Novartis cancer drug Ceritinib

      Delhi HC given Green Signal to Natco Pharma for generic of Novartis cancer drug Ceritinib

      Farhat Nasim1 Sept 2019 2:33 PM IST
      New Delhi: In a major relief to Natco, the Delhi High Court has lifted a ban on Natco Pharma from manufacturing fresh stock of on-small cell lung...
      Biocon gets 4 observations, Complete Response Letter from USFDA for Insulin Glargine

      Biocon gets 4 observations, Complete Response Letter from USFDA for Insulin Glargine

      Farhat Nasim1 Sept 2019 10:15 AM IST
      The United Food and Drug Administration (USFDA) has also issued four observations after cGMP inspection of one of Biocon's biologics drug product...
      5 pc GDP should act as wake-up call for Government to act more: Kiran Mazumdar Shaw

      5 pc GDP should act as wake-up call for Government to act more: Kiran Mazumdar Shaw

      Farhat Nasim1 Sept 2019 10:00 AM IST
      Kiran Mazumdar Shaw, who heads the south-headquartered Biocon, said the economic growth data clearly suggests a fall in consumption which needs to be...
      Hospitals permitted to add trade margin on orthopaedic knee implants: NPPA Clarification

      Hospitals permitted to add trade margin on orthopaedic knee implants: NPPA Clarification

      Farhat Nasim31 Aug 2019 2:37 PM IST
      This clarification comes after the NPPA was informed about certain Third Party Administrators (TPAs) who are not allowing trade margins to Hospitals,...
      AIOCD threatens to Boycott CIPLA if it enters into E-Pharmacy Business

      AIOCD threatens to Boycott CIPLA if it enters into E-Pharmacy Business

      Farhat Nasim31 Aug 2019 2:35 PM IST
      New Delhi: A lobby of 8.5 lakh chemists across the country is planning to boycott the products manufactured by Cipla if the company enters the e...
      Glenmark Pharma gets USFDA nod for generic version of Elidel Cream to treat skin conditions

      Glenmark Pharma gets USFDA nod for generic version of Elidel Cream to treat skin conditions

      Farhat Nasim30 Aug 2019 3:26 PM IST
      The approved Pimecrolimus Cream is a generic version of Elidel Cream, 1 per cent, of Bausch Health US, LLC, Glenmark Pharma said.New Delhi: Glenmark...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok